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Abstract: Therapies to treat patients infected with human immunodeficiency virus (HIV) aim at pre-
venting viral replication but fail to eliminate the virus. Although transplantation of allogeneic CCR5Δ32
homozygous stem cell grafts provided a cure for a few patients, this approach is not considered a gen-
eral therapeutic strategy because of potential side effects. Conversely, gene editing to disrupt the C-C
chemokine receptor type 5 (CCR5) locus, which encodes the major HIV coreceptor, has shown to confer
resistance to CCR5-tropic HIV strains. Here, an engineered transcription activator-like effector nucle-
ase (TALEN) that enables efficient CCR5 editing in hematopoietic cells is presented. After transfer-
ring TALEN-encoding mRNA into primary CD4+ T cells, up to 89% of CCR5 alleles are disrupted.
Genotyping confirms the genetic stability of the CCR5-edited cells, and genome-wide off-target anal-
yses established the absence of relevant mutagenic events. When challenging the edited T cells with
CCR5-tropic HIV, protection in a dose-dependent manner is observed. Functional assessments reveal no
significant differences between edited and control cells in terms of proliferation and their ability to secrete
cytokines upon exogenous stimuli. In conclusion, a highly active and specific TALEN to disrupt CCR5
is successfully engineered, paving the way for its clinical application in hematopoietic stem cell grafts.
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Therapies to treat patients infected with human immunodeficiency virus
(HIV) aim at preventing viral replication but fail to eliminate the virus.
Although transplantation of allogeneic CCR532 homozygous stem cell grafts
provided a cure for a few patients, this approach is not considered a general
therapeutic strategy because of potential side effects. Conversely, gene editing
to disrupt the C-C chemokine receptor type 5 (CCR5) locus, which encodes the
major HIV coreceptor, has shown to confer resistance to CCR5-tropic HIV
strains. Here, an engineered transcription activator-like effector nuclease
(TALEN) that enables efficient CCR5 editing in hematopoietic cells is
presented. After transferring TALEN-encoding mRNA into primary CD4+ T
cells, up to 89% of CCR5 alleles are disrupted. Genotyping confirms the
genetic stability of the CCR5-edited cells, and genome-wide off-target analyses
established the absence of relevant mutagenic events. When challenging the
edited T cells with CCR5-tropic HIV, protection in a dose-dependent manner is
observed. Functional assessments reveal no significant differences between
edited and control cells in terms of proliferation and their ability to secrete
cytokines upon exogenous stimuli. In conclusion, a highly active and specific
TALEN to disrupt CCR5 is successfully engineered, paving the way for its
clinical application in hematopoietic stem cell grafts.
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1. Introduction
As of today, there is no cure for infection
with human immunodeficiency virus type
1 (HIV-1). The available antiretroviral ther-
apies (ART) target different steps in the
HIV replication cycle. Although ART man-
ages to reduce the HIV burden below the
detection limit as long as the medication
is taken, it does not eradicate the virus.
Inhibition of HIV entry has been consid-
ered a promising strategy that was explored
in numerous ways. In particular, target-
ing C-C chemokine receptor type 5 (CCR5),
the co-receptor of prevalent HIV-1 strains
has been pursued using CCR5 inhibitors,
or blocking antibodies.[1] But again, even
when combined with other ARTs, they do
not eradicate HIV.
On the other hand, the knowledge that
a naturally occurring 32 nucleotide deletion
(∆32) mutation in the CCR5 locus leads to
resistance to CCR5-tropic (R5-tropic) HIV-1
strains,[2,3] has spurred some encouraging
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approaches.[4] People with a homozygous Δ32 mutation are rare,
clinically unremarkable, and conduct a normal life.[5] In 2007,
an HIV-positive patient, later referred to as the “Berlin Patient,”
was transplanted with an allogeneic stem cell graft of an human
leukocyte antigen (HLA)-matched donor homozygous for the
CCR5Δ32 mutation after diagnosis of acute myeloid leukemia.
After stopping ART, the patient was closely monitored for virus
titers. As of today, that is, 13 years later, no viral RNA or provi-
ral DNA has been detected, so that he was declared the first pa-
tient to be cured of HIV.[6–8] Following the principle of the Berlin
patient, two more patients, known as the London[9,10] and the
Düsseldorf[11] patients, might be declared as cured. These obser-
vations underline the possibility to transfer HIV resistance from
a donor to a patient. However, due to the potentially severe side
effects of allogenic transplantations and the difficulty of finding
matching homozygous Δ32 donors, this strategy is not consid-
ered a universal approach to treat patients affected by HIV.
Alternatively, CCR5 gene editing in autologous cells repre-
sents a potent approach to provide patients with cells resistant
to HIV.[12] To this end, genome editing with programmable nu-
cleases, in particular, zinc-finger nucleases (ZFN), transcription
activation-like effector nucleases (TALENs), MegaTALs, and clus-
tered regularly interspaced short palindromic repeat/CRISPR-
associated protein (CRISPR-Cas) nucleases, have been used in
several preclinical and clinical studies to disrupt the CCR5 gene
in primary human CD4+ T cells or hematopoietic stem and pro-
genitor cells (HSCs).[13–22] In a clinical trial conducted by Tebas
et al., 12 individuals living with HIV received a single dose of
CCR5-edited autologous CD4+ T cells. Although the effect lasted
only transiently, the blood level of HIV provirus decreased in
most patients and the infusion of CCR5-modified autologous
CD4+ T cells proved to be safe.[15] To achieve long-lasting effects,
however, CCR5 must be modified in HSCs. This ensures that
HIV resistance will be conferred to all CD4+ immune cells, that
is, alsomacrophages and dendritic cells. In reported clinical scale
validation runs, 25–71% of CCR5 alleles were edited in HSCs
but the used ZFN revealed high off-target (OT) activities,[18] sug-
gesting a relevant genotoxic potential in the stem cell compart-
ment. HSCs were also edited with CRISPR-Cas nucleases for
the treatment of an HIV-positive patient with acute lymphocytic
leukemia. The CCR5 editing frequency in the graft was ≈18%
and was further diluted by the concomitant transplantation of
unedited HSCs. Not surprisingly, HIV rebound was observed
during treatment interruption.[20] Hence, while the concept of
conferring HIV resistance by disrupting CCR5 has been known
for over a decade, the employed designer nucleases revealed low
to intermediated disruption efficiencies (usually 20–50% allelic
knockout frequencies) and/or undesirable OT effects. We con-
jecture that for a CCR5 editing approach to be successful in the
clinic,CCR5 editing inHSCsmust be both highly efficient,>50%
biallelic knockout, and highly specific, to provide the patient with
a safe graft and a sufficient number of HIV-resistant immune
cells.
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In our study, we validated a novel TALEN for its ability to dis-
rupt the CCR5 allele with both high activity and high specificity,
using settings transferrable to clinical-grade manufacturing. To
demonstrate resistance to infection with HIV-1, CCR5 editing
was performed in primary CD4+ T cells. While TALENs were
employed to disrupt CCR5 in human cells before,[16,23,24] here we
show that an improved TALEN design in combination with novel
RNA transfer technologies[25] enabled us to knockout CCR5 in
CD4+ T cells with high activity and high specificity. The manu-
factured T cells were HIV resistant, genetically stable, and main-
tained their potency.
2. Results
2.1. CCR5 Knockout is Genetically Stable in CD4+ T Cells
The target locus in exon 3 of the CCR5 gene was chosen to
be in the region coding for the N-terminus of the CCR5 pro-
tein (Figure 1A). The rationale was twofold: 1) out-of-frame
insertion/deletion (indel) mutations would cause frameshift
mutations that lead to early termination of translation, and 2)
this sequence stretch codes for a conserved region of CCR5
that is bound by HIV-1 gp120. Even in-frame indel mutations
will remove critical residues necessary for HIV-1 to bind to
CCR5.[26,27] We first established the optimal conditions to
achieve high CCR5 disruption in CD4+ T cells from different
donors with TALEN encoding mRNA via electroporation. Cells
were cultivated for several days and subjected to genotyping at
days 7 and 21 of culture to monitor gene disruption frequencies.
To this end, we employed the T7 endonuclease I (T7E1) assay,
a simple test for detecting targeting efficiency in gene-edited
cells based on the T7E1’s ability to recognize indel mutations
on PCR fragments generated from the target locus. A transient
temperature shift to 32 °C increased allelic CCR5 disruption
frequency from 50% to 85% (Figure 1B). The indel frequencies
ranged between 50–90% at day 7 of culture and stabilized around
85% after 21 days, demonstrating stable editing in long term
cultures. We also evaluated the effect of the gene disruption
on the surface expression of CCR5. CCR5 expression varies
between cell subsets and donors[28] as well as during activation,
therefore staining was performed at the same culture stage. The
percentage of CCR5 positive cells was significantly decreased (p
= 0.0009) after editing with TALEN while no significant decrease
in CCR5 expression was detected in control samples treated
with only the left TALEN arm (Figure 1C). Reduction of CCR5
protein expression remained significant (p = 0.0314) and stable
for 21 days, which paired well with the observations made on the
genomic level (Figure 1B).
In parallel, we edited cells from a Δ32 heterozygous donor. Al-
lelic gene disruption rates reached 69% on day 7 and 86% on
day 21 (Figure 1B), so well within the ranges of the homozygous
CCR5 wt donors.When performing a phenotypic analysis, a drop
of 50% in CCR5 expression was also observed for this donor (Fig-
ure 1C, red dots), in line with the results seen with the homozy-
gous donors.
To better understand the type of indels generated by the nucle-
ases, we performed next-generation sequencing (NGS) analysis
on the edited CCR5 target locus in three different donors, one of
which being Δ32 heterozygous, and analyzed the indels at days
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Figure 1. Stable CCR5 knockout in CD4+ T cells. A) Schematic of theCCR5locus with TALEN binding sites (boxes). B) Quantification of TALEN activity.
T7E1 assays were performed in CD4+ T cells at days 7 or 21 post-electroporation. Where indicated, cells were transiently incubatedat 32 °C for 24 h.
Samples derived from a Δ32 heterozygous donor are highlighted in red (n= 3–7 donors; ±SD). C) CCR5 expression in CD4+ T cells. Cells were elec-
troporated with only left TALEN arm (L+L) or both TALEN arms (L+R). Data is shown relative to untreated (UT) cells. Each dot represents a different
donor (n= 2–7; ±SD; ns = not significant, nd = not determined, *p ≤ 0.05; ***p ≤ 0.001, pairedt-test). D) Frequency of mutations. Targeted amplicon
sequencing of the target site was performed after 7 and 21 days of culture (n= 3 donors;±SD). Displayed are the frequencies of all indels with a frequency
1 in at least one of the three experiments. E) The sequence of induced mutations. Displayed are all sequences quantified in (D).
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Figure 2. CCR5disruption confers HIV-1 resistance. A)Challenge withlentiviralvector. Untreated (UT) cells as well as TALEN-edited cells (L+L; L+R)
were transduced with GFP-expressing lentiviral particles (6 transducing units per cell) that were either pseudotyped with VSV-G or HIV-1BaL-gp160.
Challenge was performed at days 7 and 21 of culture. Indicated is the percentage of GFP-positive cells relative to the corresponding untreated cells.
Samples derived from two Δ32 heterozygous donors are marked in red. Each dot represents a different donor (n= 3-7; ±SD; ns = not significant, *p ≤
0.05; **p ≤ 0.01, pairedt-test). B–D) Challenge with HIV-1. Shown is the p24 kinetics over 12 days of infection in untreated (UT), TALEN edited cells
(L+R 100), and edited cells spiked with UT at ratios of 1:1 (L+R 50) or 1:3 (L+R 25). Cells were challenged with HIV-1JRFL at MOIs of 0.001 (B) or 0.01
(C), or with HIV-1NL3-4 at MOIs of 0.01 or 0.001 (D) in triplicates ±SD.
7 and 21, respectively (Figure 1D,E). The indel patterns and fre-
quencies remained comparable between samples and over time.
There was no significant enrichment or depletion of a specific
indel type detected by a paired t-test during the culture period.
This indicates that the clonal distribution of the edited cells be-
tween the two timepoints remained stable. In all three donors,
the most frequent indel was a 19-nt deletion, followed by a 9-nt
deletion, that combined represented about 20% of the total indel
mutations. Of note, the four most frequent deletions −19, −9,
−13, and −26 are likely due to microhomologies, as detected by
the Microhomology-Predictor tool.[29]
2.2. CCR5-Edited CD4+ T Cells are Resistant to HIV-1 Infection
As a proof of concept, we challenged the edited cells at an early
and late culture timepoint with GFP expressing lentiviral vectors
pseudotyped with either the gp160 glycoprotein of the HIV-1
R5-tropic strain BaL or VSV-G as control. The CCR5 edited
CD4+ T cells showed ≈50% reduced susceptibility to transduc-
tion with the HIV-gp160 pseudotyped vector when compared
to control cells (Figure 2A). When challenging T cells from two
Δ32 heterozygous donors, a decreased susceptibility—similar
to cells from the other donors—was observed. As a CD4/CCR5-
independent transduction control, we transduced the cells in
parallel with VSV-G pseudotyped lentivectors. Under these con-
ditions, we did not see any alteration in transduction efficiency.
Next, we tested the resistance of CCR5-edited CD4+ T cells to
replication-competent HIV-1 by infecting them with either R5-
tropic HIV-1JRFL or CXCR4-tropic (X4-tropic) HIV-1NL4-3. HIV-1
p24 was quantified in the supernatant of infected cells as a mea-
sure of viral replication (Figure S1A,B, Supporting Information).
In samples infected with HIV-1JRFL (high or low multiplicity of
infection [MOI]), a significant protective effect (p = 8.8 × 10–4
and p = 5.7 × 10–5) was observed when compared to infection of
unedited cells. As expected, infections with X4-tropic HIV-1NL4-3
did not reveal significant differences (Figure S1B, Supporting In-
formation). Furthermore, to investigate the impact of the edit-
ing rate on the viral replication, we spiked edited CD4+ T cells
with unedited cells at ratios of 1:1 (50% edited cells) and 1:3 (25%
edited cells). Low MOI infection with HIV-1JRFL, as determined
by p24 in the supernatant, was significantly (p = 2.72 × 10–14)
reduced in non-diluted edited cells (100%) when compared to
unedited samples (Figure 2B). The protective effect was also ob-
served in both the 50% and 25% mix (p = 8.38 × 10–11, p =
1.13 × 10–4), suggesting that a cell population with ≈20% of
editedCCR5 alleles was able to slow down virus replication. A sig-
nificant protective effect (p= 3.06× 10–3) was also observed when
edited cells (100%) were infected with a highMOI (Figure 2C), al-
beit to a lower degree as compared to the lowMOI infection. After
dilution (50%mix), the protective effect was lost when cells were
infected at highMOI (p = 0.98). In the control settings with HIV-
1NL4-3 infections, we did not see any impairment of virus repli-
cation in the edited cells (Figure 2D), as expected. We conclude
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Figure 3. CCR5disruption does not impair CD4+ T cell functions. A) Viability. Shown is the viability of CD4+ T cells 24 h after mock-electroporation
(Pulse), or electroporation with mRNA (GFP/TALEN L+L/TALEN L+R) relative to untreated (UT) cells (n= 4–12; *p≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001;
±SD). B,C) Proliferation. Shown are the growth curves of CD4+ T cells subjected to transient temperature shift to 32 °C (B) or kept at 37 °C (C), after
mock-electroporation (Pulse) or electroporation with mRNA (GFP, TALEN arms L+L/L+R), or left untreated (UT). Cells were counted at the indicated
timepoints. Error bars represent ±SD. D–F) Cytokine secretion. Cytometric bead array was used to assess the release of TNF-𝛼 (D), IFN-𝛾 (E), or IL-2
(F) at indicated timepoints after stimulation (n= 3, ±SD).
that editing of CD4+ T cells with CCR5 targeting TALEN leads to
protection against R5-tropic HIV-1 in an editing dose-dependent
manner.
2.3. CCR5-Edited CD4+ T Cells Maintain Potency
Transfer of mRNA to T cells via electroporation can potentially
affect cell viability and/or functionality. We addressed this point
by evaluating viabilities 24 h post-treatment. CD4+ T cells
electroporated with TALEN mRNA (both arms, or left arm only),
GFP mRNA, or mock pulsed, showed a decrease in viabilities
of ≈30% when compared to untreated samples (Figure 3A),
implying that the electric pulse but not the RNA transfer had
an impact on T cell viabilities. On the other hand, the transient
temperature shift to 32 °C did not affect viability.
Next, we wanted to investigate if CCR5-edited cells retain their
proliferative potential. To this end, the edited CD4+ T cells and
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control samples were cultivated under proliferation activating
conditions. The total number of cells at days 7, 14, and 21 were
comparable for all tested conditions (Figure 3B,C). A time-series
analysis[30] confirmed that the samples, independent of cultiva-
tion temperature or treatment, did not show significant differ-
ences in proliferation. Hence, we conclude that editing CCR5 did
not affect the expansion capabilities of CD4+ T cells.
To explore if editing CCR5 has an impact on CD4+ T cell func-
tion in terms of cytokine release upon stimulation, we stimulated
the cells with either phorbol 12-myristate 13-acetate (PMA), iono-
mycin or CD3/CD28/CD2 to trigger the release of TNF-𝛼, IFN-𝛾
or IL-2, respectively. Supernatants of electroporated T cells were
harvested 8–48 h after stimulation and analyzed by cytometric
bead array. While we observed variations in the amounts of se-
creted cytokines among the four donors, the values did not sig-
nificantly (two-sided t-test) differ when comparing the various
treatment regimens (Figure 3D–F). Unstimulated cells did not
release measurable amounts of cytokines. In sum, these results
demonstrate that editing CCR5 did not impair the ability of the
engineered CD4+ T cells to respond to the different stimuli.
2.4. Editing CCR5 in CD4+ T Cells with High Specificity
To assess the genotoxic potential of TALEN mediated editing of
CCR5, we investigated the occurrence of OT activity by two dif-
ferent means: targeted amplicon sequencing of in silico predicted
OTs or an unbiased in cellula assay. The top 20 potential OTs
were predicted using the PROGNOS tool.[31] Amplicons from
edited samples were compared to amplicons of untreated sam-
ples (Figure 4A). Two of the top 20 predicted OTs revealed some
low but significant OT activity over background (Table S2, Sup-
porting Information). However, both OT01 (0.12% versus 0.10%
background, p = 0.000 211) and OT10 (0.08% versus 0.07% back-
ground, p= 0.004422) are situated in intronic regions. These data
were complemented with an unbiased OT detection approach
termed oligonucleotide capturing assay (OCA), which is based
onGUIDE-seq.[32] The highest score (OCA1) was obtained for the
CCR5 target site (Figure 4B). While OT01 was also found by OCA
(OCA03), OT10 did not match with any of the top 24 OCA hits
(Table S3, Supporting Information). On the other hand,CCR2 did
not come up as a potential OT in PROGNOS but a weak activity
at CCR2 was picked up by OCA (OCA4). Importantly, however,
all identified OCA sites had a considerably lower score than the
CCR5 on-target site (OCA1). Together, these OT analyses demon-
strate that the employed TALENs are highly specific designer nu-
cleases with minimal OT activity.
3. Discussion
Approaches to disrupt CCR5 in human primary CD4+ T cells
and HSCs have been previously described.[13–22] These reports
demonstrated the feasibility of abrogating HIV entry, albeit with
some drawbacks. This includes low gene disruption efficiencies,
high off-target effects or absence of specificity analyses, miss-
ing potency analyses, and/or lack of compatibility with good
manufacturing practice (GMP).[16,33–35] In this study, we present
efficient editing of the CCR5 locus in primary CD4+ T cells in
Figure 4. Off-target analysis in TALEN-edited CD4+ T cells. A) Targeted
amplicon sequencing of the top 20 OTs predicted by PROGNOS and an-
alyzed by CRISPResso2 (**p ≤ 0.01, ***p ≤ 0.001). B) Oligonucleotide-
capture assay (OCA) performed in CD4+ T of three donors and measured
in triplicate. Bars represent mean ± SD of all nine measurements after
subtraction of scores obtained for mock-treated cells.
a GMP-compatible manner. GMP compatibility is defined as a
condition that uses GMP-compliant devices and research-grade
reagents that are available as GMP-grade material as well. Under
these specifications, we disrupted up to 90% of CCR5 alleles
with no notable off-target activity, suggesting that the employed
TALEN are highly specific. Disrupting the region that encodes
the N-terminus of the CCR5 protein in CD4+ T cells gave
rise to cells resistant to infection with R5-tropic HIV-1 but, as
expected, not X4-tropic virus. Importantly, CCR5-edited CD4+
T cells did not show any differences to non-edited control cells
in the applied proliferation and potency assays. This indicates
that TALEN-mediated editing of CCR5 is efficacious and safe,
opening a window for therapeutic applications in CD34+HSCs.
Our data further demonstrate that lowCCR5 editing frequency
is not sufficient to abrogate HIV infection, putting forward that
efficient disruption that mediates bi-allelic gene knockouts are
paramount to see clinical effects.[15] This is in line with a recently
published case report confirming that a CCR5 knockout fre-
quency of 18% in transplanted HSCs is not sufficient to achieve
clinical benefit.[20] Another crucial point for a clinical trial is to re-
cruit patients exclusively positive for R5-tropicHIV variants since
the absence of CCR5 would favor the propagation of X4-tropic
viruses if present in the patient. The importance of proper ex-
amination was seen in the “Essen patient”[36] who suffered from
an X4 rebound after allogenic transplantation of a Δ32 homozy-
gous HSC graft. Performing a knockout of both coreceptor en-
coding loci, CCR5 and C-X-C chemokine receptor type 4 (CXCR4),
can be considered for CD4+ T cells[19,37,38] but not for HSCs, as
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CXCR4 is essential, for example, for HSC homing and B cell
development.[39,40]
A side effect of gene editing approaches is genotoxicity as a
consequence of OT effects. OT activity can induce mutagenesis
but also provoke chromosomal rearrangements, both potentially
inducing cellular transformation. Employing highly specific de-
signer nucleases is therefore paramount to mitigate the risk of
such effects. Several tools are available to identify OT events, in-
cluding in silico predictions which were used in[16,34] and known
to miss important OTs. Another study[33] performed OT analysis
using whole-genome sequencing, which is unable to detect rare
OT events. In our study, we carefully evaluated OTs using both
in silico prediction as well as by employing the unbiased, cell-
based oligonucleotide capturing assay (OCA). We detected two
rare OT events occurring in introns of genes, thus minimizing
the risks of adverse effects. For instance, OT1/OCA3 in CNOT10
was cleaved in 0.12% of cells. OCA identified three additional
OTs, one of them in the CCR2 gene. The OCA scores of these
OTs were similarly low as for OCA3, suggesting OT activities in
the range of 0.1%.While editing in terminally differentiated cells,
like CD4+ T cells, mitigates the risk of developing malignancies,
this is not the case for genome editing in long-lived multipotent
stem cells. Importantly, all functional assays we performed in
this study demonstrated that the CCR5-edited cells behaved as
unedited cells, suggesting that TALEN expression did not have
any negative impact on these cells. All in all, we demonstrate that
our novel designed TALEN mediates CCR5 disruption with high
frequency and with low genotoxicity, so paving the way for clini-
cal translation in CD34+ hematopoietic stem cells.
4. Experimental Section
CD4+ T Cells Cultivation and Editing: PBMCs were isolated from the
leukocyte reduction system chambers obtained from the Blood Donation
Center after informed donor consent. CD4+ T cells were isolated using
CD4 MicroBeads (Miltenyi, Germany) and cryopreserved. After thawing,
cells were cultivated in X-Vivo15 (Lonza, Switzerland) supplemented with
20 U mL−1 IL-2 (Miltenyi) and activated with T Cell Activation/Expansion
Kit (Miltenyi). After 3 days, beads were removed and electroporation was
performed by combining 5 × 106 CD4+ T cells with 10 µg of each TALEN
mRNA or 5 µg of GFP mRNA.[41] Cells were electroporated in 100 µL elec-
troporation buffer using P3 Primary Cell 4D-Nucleofector kit (Lonza) and
program EO-115 or in 200 µL of BTXpress Cytoporation medium T (BTX,
Harvard Bioscience, USA) (1 pulse 1200 V, 0.1 ms, 0.2 ms interval, 1 pulse
1200 V, 0.1 ms, 100ms interval and 4 pulses 130 V, 0.2 ms, 2 ms intervals).
For long-term culture, CD4+ T cells were reactivated with T Cell Activa-
tion/Expansion Kit every 7 days. The number of cells was determined on
an automated cell analyzer (NucleoCounter NC-250, ChemoMetec, Den-
mark). Genomic DNA was extracted with DNeasy Blood & Tissue Kits (Qi-
agen, Netherlands). NGS or T7E1 assay was performed and analyzed as
previously described.[42]
mRNA Production: For in vitro RNA transcription, 10 µg of the TALEN
encoding plasmid containing a T7 promoter and an encoded poly(A) was
linearized, purified with QIAquick Gel Extraction Kit (Qiagen), and RNA
transcribed with mMESSAGE mMACHINE T7 Ultra kit (ThermoFisher,
USA). The RNA pellets were resuspended in EB buffer (Qiagen) and stored
at −80 °C.
Lentiviral Transduction: For production,[43] HEK293T cells (ATCC,
CRL-3216) were grown in DMEM GlutaMAX I (Life Technologies, USA)
supplemented with 10% FCS (GE Healthcare, UK), 10.000 U mL−1 peni-
cillin, and 10 mg mL−1 streptomycin (GE Healthcare), and 100 mm
sodium pyruvate (PAA, Austria). 15 × 106 cells were seeded per 15 cm
plate 24 h before transfection. Before transfection, the medium was
supplemented with chloroquine 1:1000 (Sigma-Aldrich, Germany), and
polyethyleneimine transfection performed with 15 µg pMDLg/pRRE (Ad-
dgene), 3 µg pRSV-Rev (Addgene), 15 µg of the lentivirus encoding plas-
mid, and 5.1 µg of the envelope encoding plasmid (Bal_gp120, a kind gift
of Dr. Boris Fehse, or pMD2.G, Addgene). After 12 h, the transfection mix
was exchangedwith amedium containing 10mmsodiumbutyrate (Sigma-
Aldrich). Supernatants were harvested 32 h and 56 h post-transfection,
pelleted at 20 000 × g at 4 °C for 2 h on a 20% sucrose cushion using a
swingout rotor. Pellets were resuspended in 50 µL of PBS and stored at
−80 °C. For titration, lentiviral EGFP vectors were titrated on 5 × 104 PM1
cells (NIH AIDS Reagent Program[44]), cultivated in RPMI 1640 medium
containing l-Glutamine (Life Technologies), 10% FCS (GE Healthcare),
10.000 UmL−1 penicillin, and 10 mgmL−1 streptomycin (GE Healthcare),
and supplemented with 4 µg mL−1 polybrene, by spinoculation for 1 h at
200 × g at 32 °C. For transduction, 5 × 104 CD4+ T cells were cultured in
X-Vivo15 medium (Lonza) containing 4 µg mL−1 polybrene with 6 trans-
ducing units per cell by spinoculation as above.
Flow Cytometry: GFP expression after lentiviral transduction and/or
cell viability (7AAD, AppliChem, Germany) were assessed using BD Ac-
curi C6 Flow Cytometer (BD Biosciences, USA). CCR5 expression was de-
tected by labeling 1 × 105 cells in 50 µL of PBS with 2 µL of APC-labeled
mouse anti-human CD195 antibody (BD Biosciences) for 20 min at room
temperature. Cells were analyzed on BD FACS Canto-II (BD Biosciences).
HIV-1 Infection: HIV-1 provirus encoding plasmids were obtained
from the NIH AIDS Research and Reference Reagent Program.[45,46] Virus
stocks HIV-1JR-FL (R5-tropic) and HIV-1NL4-3 (X4-tropic) were generated
and titrated as previously described.[47] For infection, 2× 105 CD4+ T cells
were activated as above and infected with either HIV-1JR-FL or HIV-1NL4-3
at MOIs of 0.01 and 0.001. At indicated timepoints, 50 µL of cell culture
supernatant was harvested and used to determine p24 concentration by
ELISA.[48]
Cytokine Release: 200 µL of supernatants were harvested from
1 × 106 cells per sample at indicated timepoints. Cytokine concentrations
were determined using the Cytometric Bead Array for IFN-𝛾 , IL-2, or TNF-𝛼
(BD Biosciences). Cells were stimulated with CD3/CD28/CD2 beads (Mil-
tenyi), 1 µg mL−1 ionomycin (Merck-Millipore, Germany), or 10 ng mL−1
PMA (Sigma-Aldrich).
Off-Target Analyses: Potential OTs were predicted with PROGNOS
(http://bao.rice.edu/cgi-bin/prognos/prognos.cgi) using the TALEN v2.0
algorithm.[31] Five mismatches per half-sites were allowed. Loci were
PCR amplified using primers listed in Table S1, Supporting Informa-
tion. Libraries were prepared with NEBNext Ultra II DNA Library Prep
Kit (NEB), quantified with ddPCR Library Quantification Kit for Illumina
TruSeq (Biorad, Germany), sequenced on Illumina MiSeq platform us-
ing MiSeq Reagent Kit v2, 500-cycles (Illumina, USA), and data ana-
lyzed with CRISPResso2.[49] p values were adjusted with the Benjamini
& Hochberg[50] method. For OCA, 1 × 106 PBMCs (ALLCELLS, USA)/mL
in X-Vivo15 medium (Lonza), supplemented with 5% human AB serum
(Gemini, USA) and 20 ng mL−1 of IL-2 (Miltenyi), were activated using
human T activator CD3/CD28 (ThermoFisher). 4 days later, 5 × 106 T
cells in cytoporation medium T were electroporated with 20 µg of TALEN
mRNA (10 µg per subunit) and 10 µL of pre-annealed oligodeoxynu-
cleotides (dsODN, 100 µm) using AgilePulse MAX system (Harvard Ap-
paratus, USA) and a 0.4 cm cuvette. Genomic DNA was extracted 3 days
later, randomly sheared to 300 bp fragments by sonication (Covaris LE220-
plus), fragments end-repaired/A-tailed (NEBNext Ultra End Repair/dA-
Tailing Module), and NGS Y-adapters (TruSeq Annealed Adapter) added.
Two rounds of anchored PCR using dsODN-specific and adapter-specific
primers were performed. Adapter-specific (P5_1) and dsODN-specific
primers were used in the first PCR. Adapter-specific (P5_2) primers,
dsODN-specific primers P7, and primers adding the barcode and P7 se-
quence to the ends of the PCR product were used in the second PCR. PCR
products were pooled and sequenced using IlluminaNextSeq (2× 150 bp).
The resulting sequences reads were mapped to the human genome to
identify potential OT sites.
Statistical Analyses: A time series analysis was performed to com-
pare the samples in both the HIV-1 challenge and growth curves
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experiments.[30] The goodness of the fit between the full and the reduced
models was tested by Anova where p-value indicates the probability that
the two models were the same. p-values are indicated with * ≤ 0.05; **
≤ 0.001; *** ≤ 0.0001. For all other analyses, the Student’s t-test was ap-
plied.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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